AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Luca Gianni; Gilles H Romieu; Michail Lichinitser; Sergio V Serrano; Mauro Mansutti; Xavier Pivot; Paola Mariani; Fabrice Andre; Arlene Chan; Oleg Lipatov; Stephen Chan; Andrew Wardley; Richard Greil; Nicola Moore; Sylvie Prot; Celine Pallaud; Vladimir Semiglazov

doi:10.1200/JCO.2012.44.7912

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Luca Gianni, Gilles H Romieu, Michail Lichinitser, Sergio V Serrano, Mauro Mansutti, Xavier Pivot, Paola Mariani, Fabrice Andre, Arlene Chan, Oleg Lipatov, Stephen Chan, Andrew Wardley, Richard Greil (Co-author), Nicola Moore, Sylvie Prot, Celine Pallaud, Vladimir Semiglazov

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

201 Citations (Web of Science)

Original language	English
Pages (from-to)	1719-1725
Journal	JOURNAL OF CLINICAL ONCOLOGY
Volume	31
Issue number	14
DOIs	https://doi.org/10.1200/JCO.2012.44.7912
Publication status	Published - 2013

Keywords

ERBB2 OVEREXPRESSION
PLUS DOCETAXEL
CELLS
ANGIOGENESIS
CHEMOTHERAPY
EXPRESSION
VEGF
HER2

Access to Document

10.1200/JCO.2012.44.7912

Cite this

Gianni, L., Romieu, G. H., Lichinitser, M., Serrano, S. V., Mansutti, M., Pivot, X., Mariani, P., Andre, F., Chan, A., Lipatov, O., Chan, S., Wardley, A., Greil, R., Moore, N., Prot, S., Pallaud, C., & Semiglazov, V. (2013). AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. JOURNAL OF CLINICAL ONCOLOGY , 31(14), 1719-1725. https://doi.org/10.1200/JCO.2012.44.7912

Gianni, Luca ; Romieu, Gilles H ; Lichinitser, Michail et al. / AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. In: JOURNAL OF CLINICAL ONCOLOGY 2013 ; Vol. 31, No. 14. pp. 1719-1725.

@article{55f89eb6cdd440d188a255eeea90a0e4,

title = "AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.",

keywords = "ERBB2 OVEREXPRESSION, PLUS DOCETAXEL, CELLS, ANGIOGENESIS, CHEMOTHERAPY, EXPRESSION, VEGF, HER2",

author = "Luca Gianni and Romieu, {Gilles H} and Michail Lichinitser and Serrano, {Sergio V} and Mauro Mansutti and Xavier Pivot and Paola Mariani and Fabrice Andre and Arlene Chan and Oleg Lipatov and Stephen Chan and Andrew Wardley and Richard Greil and Nicola Moore and Sylvie Prot and Celine Pallaud and Vladimir Semiglazov",

year = "2013",

doi = "10.1200/JCO.2012.44.7912",

language = "English",

volume = "31",

pages = "1719--1725",

journal = "JOURNAL OF CLINICAL ONCOLOGY ",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

number = "14",

}

Gianni, L, Romieu, GH, Lichinitser, M, Serrano, SV, Mansutti, M, Pivot, X, Mariani, P, Andre, F, Chan, A, Lipatov, O, Chan, S, Wardley, A, Greil, R, Moore, N, Prot, S, Pallaud, C & Semiglazov, V 2013, 'AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.', JOURNAL OF CLINICAL ONCOLOGY , vol. 31, no. 14, pp. 1719-1725. https://doi.org/10.1200/JCO.2012.44.7912

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. / Gianni, Luca; Romieu, Gilles H; Lichinitser, Michail et al.
In: JOURNAL OF CLINICAL ONCOLOGY , Vol. 31, No. 14, 2013, p. 1719-1725.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

AU - Gianni, Luca

AU - Romieu, Gilles H

AU - Lichinitser, Michail

AU - Serrano, Sergio V

AU - Mansutti, Mauro

AU - Pivot, Xavier

AU - Mariani, Paola

AU - Andre, Fabrice

AU - Chan, Arlene

AU - Lipatov, Oleg

AU - Chan, Stephen

AU - Wardley, Andrew

AU - Greil, Richard

AU - Moore, Nicola

AU - Prot, Sylvie

AU - Pallaud, Celine

AU - Semiglazov, Vladimir

PY - 2013

Y1 - 2013

KW - ERBB2 OVEREXPRESSION

KW - PLUS DOCETAXEL

KW - CELLS

KW - ANGIOGENESIS

KW - CHEMOTHERAPY

KW - EXPRESSION

KW - VEGF

KW - HER2

U2 - 10.1200/JCO.2012.44.7912

DO - 10.1200/JCO.2012.44.7912

M3 - Original Article

C2 - 23569311

SN - 0732-183X

VL - 31

SP - 1719

EP - 1725

JO - JOURNAL OF CLINICAL ONCOLOGY

JF - JOURNAL OF CLINICAL ONCOLOGY

IS - 14

ER -

Gianni L, Romieu GH, Lichinitser M, Serrano SV, Mansutti M, Pivot X et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. JOURNAL OF CLINICAL ONCOLOGY . 2013;31(14):1719-1725. doi: 10.1200/JCO.2012.44.7912